Non-invasive imaging of combretastatin activity in two tumor models: Association with invasive estimates

Abstract Introduction. The efficacy of the vascular disrupting agent combretastatin A-4 phosphate (CA4P) depends on several factors including tumor size, nitric oxide level, interstitial fluid pressure, and vascular permeability. These factors vary among tumor types. The aim of this study was to investigate all these factors in two tumor models that respond differently to CA4P. Material and methods. Mice bearing C3H mammary carcinomas or KHT sarcomas (200 to 800 mm3) were intraperitoneally injected with CA4P (100 mg/kg). Tumor size and the effect of a nitric oxide inhibitor nitro-L-arginine (NLA) administered intravenously were evaluated by necrotic fraction histologically assessed at 24 hours. Interstitial fluid pressure (IFP) was measured using the wick-in-needle technique, and vascular characteristics were assessed with dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Results. Initial necrotic fraction was about 10% in both tumor models at 200 mm3, but only increased significantly with tumor size in the C3H mammary carcinoma. In this tumor, CA4P significantly induced further necrosis by about 15% at all sizes, but in the KHT tumor, the induced necrotic fraction depended on tumor size. For both tumor types, NLA with CA4P significantly increased necrotic fraction above that for each drug alone. CA4P significantly decreased IFP in all tumors except in the 800 mm3 C3H tumor, which had an initially non-significant lower value. Interstitial volume estimated by DCE-MRI increased in all groups, except the 800 mm3 C3H tumors. DCE-MRI vascular parameters showed different initial characteristics and general significant reductions following CA4P treatment. Conclusions. Both tumor models showed differences in all factors before treatment, and in their response to CA4P. Perfusion and permeability as estimated by DCE-MRI play a central role in the CA4P response, and interstitial volume and IFP seemed related. These factors may be of clinical value in the planning of CA4P treatments.

[1]  Dag Rune Olsen,et al.  DCEMRI of spontaneous canine tumors during fractionated radiotherapy: a pharmacokinetic analysis. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  T. Seierstad,et al.  MR-guided simultaneous integrated boost in preoperative radiotherapy of locally advanced rectal cancer following neoadjuvant chemotherapy. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  D. Beyersdorff,et al.  MRI before and after external beam intensity-modulated radiotherapy of patients with prostate cancer: the feasibility of monitoring of radiation-induced tissue changes using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  G. Tozer,et al.  Nitric Oxide Synthase Inhibition Enhances the Tumor Vascular-Damaging Effects of Combretastatin A-4 3-O-Phosphate at Clinically Relevant Doses , 2009, Clinical Cancer Research.

[5]  Kristine Gulliksrud,et al.  Dynamic contrast-enhanced magnetic resonance imaging of tumor interstitial fluid pressure. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  R. Maxwell,et al.  Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients. , 2008, International journal of radiation oncology, biology, physics.

[7]  P. Sonveaux.  Provascular strategy: targeting functional adaptations of mature blood vessels in tumors to selectively influence the tumor vascular reactivity and improve cancer treatment. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  K. Mouridsen,et al.  Segmentation of dynamic contrast enhanced magnetic resonance imaging data , 2008, Acta oncologica.

[9]  Ø. Bruland,et al.  DCEMRI monitoring of canine tumors during fractionated radiotherapy , 2008, Acta oncologica.

[10]  Q. Pang,et al.  The effect of combretastatin A4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours , 2008, Acta oncologica.

[11]  P. Lin,et al.  Multimodality imaging in the radiation treatment planning for a case of carcinoma of the nasopharynx , 2008, Acta oncologica.

[12]  L. Muren,et al.  Dynamic contrast enhanced magnetic resonance imaging of bladder cancer and implications for biological image-adapted radiotherapy , 2008, Acta oncologica.

[13]  P. Kristjansen,et al.  Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure. , 2007, Neoplasia.

[14]  M. Horsman,et al.  Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. , 2006, Cancer research.

[15]  Alex Vitkin,et al.  Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumors. , 2006, Cancer research.

[16]  Michael Stumm,et al.  Patupilone Induced Vascular Disruption in Orthotopic Rodent Tumor Models Detected by Magnetic Resonance Imaging and Interstitial Fluid Pressure , 2005, Clinical Cancer Research.

[17]  A. Rojiani,et al.  The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. , 2005, International journal of radiation oncology, biology, physics.

[18]  R. Mason,et al.  Tumor physiologic response to combretastatin A4 phosphate assessed by MRI. , 2005, International journal of radiation oncology, biology, physics.

[19]  Joanna Leadbetter,et al.  Magnetic Resonance Imaging Measurements of the Response of Murine and Human Tumors to the Vascular-Targeting Agent ZD6126 , 2004, Clinical Cancer Research.

[20]  Weijing Sun,et al.  Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Stephen L. Brown,et al.  Arsenic Trioxide Enhances Radiation Response of 9L Glioma in the Rat Brain , 2003, Radiation research.

[22]  K. Hori,et al.  Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis , 2003, British Journal of Cancer.

[23]  J. Griffiths,et al.  Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumor angiogenesis assessed by susceptibility magnetic resonance imaging. , 2003, Cancer research.

[24]  Martin A Lodge,et al.  Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J R Griffiths,et al.  Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging , 2003, British Journal of Cancer.

[26]  M. Horsman,et al.  Combination of vascular targeting agents with thermal or radiation therapy. , 2002, International journal of radiation oncology, biology, physics.

[27]  J. Lewin,et al.  A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. , 2002, Cancer research.

[28]  C. Kanthou,et al.  The biology of the combretastatins as tumour vascular targeting agents , 2002, International journal of experimental pathology.

[29]  J. Overgaard,et al.  Improved Tumor Response by Combining Radiation and the Vascular-Damaging Drug 5,6-Dimethylxanthenone-4-acetic Acid , 2001, Radiation research.

[30]  K. Brindle,et al.  The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. , 2001, Cancer research.

[31]  B Vojnovic,et al.  Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. , 2001, Cancer research.

[32]  J. Overgaard,et al.  Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[33]  M. Horsman,et al.  Targeting tumor blood vessels: an adjuvant strategy for radiation therapy. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[34]  P. Lambin,et al.  Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas. , 2000, European journal of cancer.

[35]  G. Tozer,et al.  Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide , 2000, British Journal of Cancer.

[36]  R. Maxwell,et al.  Combretastatins Novel Vascular targeting Drugs for Improving Anticancer therapy , 2000 .

[37]  R. Maxwell,et al.  Combretastatins novel vascular targeting drugs for improving anti-cancer therapy. Combretastatins and conventional therapy. , 2000, Advances in experimental medicine and biology.

[38]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[39]  D. Chaplin,et al.  Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. , 1999, Anticancer research.

[40]  R. Pardi,et al.  Tumor Necrosis Factor α-induced Vascular Leakage Involves PECAM1 Phosphorylation , 1996 .

[41]  R. Pardi,et al.  Tumor necrosis factor alpha-induced vascular leakage involves PECAM1 phosphorylation. , 1996, Cancer research.

[42]  J. Overgaard.  Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. , 1980, International journal of radiation oncology, biology, physics.

[43]  R. Reed,et al.  Interstitial fluid pressure in rats measured with a modified wick technique. , 1977, Microvascular research.

[44]  L. V. van Putten,et al.  Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumors. , 1967, Journal of the National Cancer Institute.